XBiotech: Rises after FDA gives nod to conduct studies for cancer drug

XBiotech

19/04/2021 12:00

** Shares of drug developer  XBIT.O  rise 12% to $18.83
premarket after FDA grants permission for co to start trials of
its drug candidate to treat pancreatic cancer  urn:newsml:reuters.com:*:nGNE7zgzPL
    ** The study will involve at least 15 top cancer centers
around the U.S, says XBIT
    ** The early-stage portion of the trial will assess
tolerability in increasing doses of the drug
    ** The mid-stage study to begin enrolling 60 patients to
receive a combination of ONIVYDE/5-FU or ONIVYDE/5-FU with
XB2001, after a safe dose has been determined - co
    ** XBIO's new drug XB2001 is a naturally occurring antibody
to block inflammation that occurs with advanced malignancies and
chemotherapy
    ** Stock up 7.4% YTD

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))